Use of interferon-alpha in laryngeal papillomatosis: eight years of the Cuban national programme.
Laryngeal papillomatosis is one of the first diseases where interferon (IFN) was found to be effective. In 1983, a programme for the treatment of all such cases started in Cuba. Up to December 1991, 125 patients (92 children, 33 adults) have been treated: 102 with leucocyte IFN-alpha, 12 with recombinant IFN-alpha-2b, and 11 have received both preparations. Case management consisted of surgical removal of the lesions followed by an IFN schedule starting with 10(5) IU/kg of weight in children or 6 x 10(6) IU in adults, i.m. daily. The dose was progressively reduced, as long as no relapses occurred. At the end of the one-year schedule the doses were reduced to 5 x 10(4) IU/kg in children or 3 x 10(6) IU in adults, weekly. If there was a relapse, it was removed surgically and the patient returned to a higher dose level. Most cases (89; 71 per cent) have not relapsed after the treatment; 60 of them have been followed for more than three years. In those with relapses, the frequency of recurrence decreased in all but four patients. The treatment seemed to be more effective if initiated less than three months after the disease onset. The tracheostomy could be removed in five out of seven patients who needed it before the IFN treatment and was necessary in only three new cases during IFN treatment. In two of these, decannulation was possible later on. In a total of 14 patients relapses persisted after several cycles of IFN treatment. They were considered resistant to such treatment. No severe side effects were reported. The most frequent ones were fever, drowsiness, increased bronchial secretion, chills and headache. The establishment of this programme has maintained the disease under control in Cuba.
Deuñas
L
L
Otorhinolaryngology Services of Hospitals throughout Cuba, Ministry of Public Health, Havana, Cuba.
Alcantud
V
V
Alvarez
F
F
Arteaga
J
J
Benítez
A
A
Bopuza
M
M
Carniege
L
L
Cartaya
B
B
Comas
C
C
Cotayo
R
R
Escobar
H
H
Fernández
H
H
Fernández
M
M
Fernández
R
R
García
M
M
Iznaga
N
N
la O
F
F
Márquez
J
J
Nordet
D
D
Pérez
J
J
Quintero
J
J
Redonavich
A
A
Robeleco
M
M
Rodríguez
H
H
Strander
H
H
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003462:Cuba; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007822:Laryngeal Neoplasms / Q000601:surgery / Q000628:therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local; D010212:Papilloma / Q000601:surgery / Q000628:therapy*; D011994:Recombinant Proteins; D013222:State Medicine; D014139:Tracheostomy
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins